News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,964 Results
Type
Article (236)
Company Profile (1)
Press Release (1727)
Section
Business (521)
Career Advice (28)
Deals (112)
Drug Delivery (1)
Drug Development (379)
Employer Resources (2)
FDA (52)
Job Trends (54)
News (1042)
Policy (76)
Tag
Academia (18)
Accelerated approval (1)
Allergies (1)
Alliances (150)
Alzheimer's disease (4)
Antibody-drug conjugate (ADC) (2)
Approvals (46)
Artificial intelligence (1)
Best Places to Work (35)
Biotechnology (1)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (2)
Cancer (21)
Cardiovascular disease (3)
Career advice (23)
CAR-T (2)
CDC (1)
Cell therapy (5)
Clinical research (299)
Collaboration (9)
Complete response letters (1)
COVID-19 (2)
C-suite (1)
Cystic fibrosis (1)
Data (5)
Depression (3)
Diabetes (1)
Diagnostics (7)
Drug discovery (2)
Drug pricing (1)
Drug shortages (1)
Duchenne muscular dystrophy (2)
Earnings (111)
Editorial (1)
Employer resources (2)
Events (284)
Executive appointments (2)
FDA (54)
Funding (3)
Generative AI (1)
Gene therapy (2)
GLP-1 (11)
Government (5)
Guidances (1)
Healthcare (67)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (4)
Infectious disease (4)
Inflammatory bowel disease (1)
Interviews (6)
IPO (44)
Job creations (19)
Job search strategy (18)
JPM (1)
Layoffs (2)
Legal (9)
Lung cancer (3)
Manufacturing (1)
MASH (1)
Medical device (18)
Medtech (18)
Mergers & acquisitions (65)
Metabolic disorders (5)
Multiple sclerosis (1)
Neurodegenerative disease (1)
Neuropsychiatric disorders (3)
Neuroscience (11)
NextGen: Class of 2026 (32)
Non-profit (20)
Obesity (4)
Opinion (4)
Patents (1)
People (186)
Phase 1 (95)
Phase 2 (133)
Phase 3 (111)
Pipeline (10)
Policy (2)
Postmarket research (3)
Preclinical (41)
Prostate cancer (1)
Radiopharmaceuticals (3)
Rare diseases (10)
Real estate (35)
Recruiting (2)
Regulatory (82)
Research institute (13)
Resumes & cover letters (5)
RSV (2)
Schizophrenia (2)
Series A (1)
Series B (1)
Sickle cell disease (1)
Sponsored (1)
Startups (16)
Stomach cancer (2)
The Weekly (2)
Vaccines (8)
Venture capital (2)
Weight loss (3)
Date
Last 30 days (4)
Last 365 days (60)
2026 (7)
2025 (61)
2024 (88)
2023 (132)
2022 (159)
2021 (169)
2020 (166)
2019 (177)
2018 (129)
2017 (101)
2016 (78)
2015 (138)
2014 (101)
2013 (88)
2012 (93)
2011 (64)
2010 (55)
Location
Africa (6)
Arizona (1)
Asia (200)
Australia (12)
California (18)
Canada (4)
China (3)
Colorado (1)
Europe (151)
Georgia (1)
Illinois (1)
Indiana (1)
Japan (1)
Massachusetts (7)
Minnesota (1)
Nevada (2)
New Jersey (1)
New York (2)
North Carolina (2)
Northern California (10)
Ohio (1)
Pennsylvania (3)
South America (6)
Southern California (6)
Tennessee (2)
Texas (3)
United States (48)
Utah (1)
Virginia (1)
Washington State (2)
1,964 Results for "notch therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell transplantation.
January 28, 2026
·
2 min read
·
Tristan Manalac
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
January 2, 2026
·
1 min read
·
Annalee Armstrong
Rare diseases
Glaukos Notches FDA Nod for Rare Eye Disorder Keratoconus
Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the drug early next year.
October 20, 2025
·
1 min read
·
Tristan Manalac
Approvals
AstraZeneca Notches Another Indication for Imfinzi, Pushing PD-L1 Blocker Into Stomach Cancer
Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
November 26, 2025
·
2 min read
·
Tristan Manalac
Weight loss
Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo
At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.
June 16, 2025
·
2 min read
·
Annalee Armstrong
Immunology and inflammation
BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis
In the plaque psoriasis arena, Sotyktu is facing off against Amgen’s Otezla and is facing the threat of upcoming competition from Alumis’ investigational TYK2 inhibitor.
March 10, 2025
·
2 min read
·
Tristan Manalac
FDA
5 Novel FDA Approvals Notched in 2024
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming particularly in the oncology and neurosciences spaces.
January 13, 2025
·
7 min read
·
Heather McKenzie
Legal
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Eli Lilly did the same in a parallel case over Zepbound’s removal from the FDA shortage list and this week a judge denied the compounders’ injunction.
March 6, 2025
·
3 min read
·
Kate Goodwin
Press Releases
Notch Therapeutics Signals a New Era in CAR-T Therapies
December 5, 2024
·
2 min read
Notch Therapeutics Promotes Chris Bond to Chief Scientific Officer
Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to announce Dr. Chris Bond has been promoted to Chief Scientific Officer.
March 28, 2023
·
1 min read
1 of 197
Next
